ADVM-062, a novel gene therapy candidate, received orphan drug designation from the FDA for the treatment of blue cone monochromacy, according to a press release from Adverum Biotechnologies. The ...
UNITED STATES, February 29, 2024 /EINPresswire.com/ -- Blue Gen Therapeutics Foundation (BGTF), a non-profit organization dedicated to advancing gene therapy ...
REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback